Empagliflozin (Jardiance)
Empagliflozin is an SGLT2 inhibitor with the broadest cardiometabolic label in its class, covering T2DM, CV risk reduction in T2DM with CVD, heart failure across the EF spectrum, and CKD. EMPA-REG OUTCOME was the pivotal trial establishing CV benefit for SGLT2 inhibitors.
- Mechanism of action
- Selective inhibition of SGLT2 in the proximal renal tubule, leading to glycosuria, natriuresis, plasma volume reduction, and favorable myocardial and renal energetics.
- Administration route
- Oral, once daily
FDA-approved indications (2026)
Type 2 diabetes
Glycemic control in adults and pediatrics ≥10 years.
CV risk reduction in T2DM + CVD
Reduction of CV death (EMPA-REG OUTCOME).
Heart failure
Reduction of CV death and HF hospitalization across EF (EMPEROR-Reduced, EMPEROR-Preserved).
Chronic kidney disease
Reduction of kidney disease progression and CV death (EMPA-KIDNEY 2023).
Dosing: adult, renal, and hepatic
| Population | Dose |
|---|---|
| T2DM | Start 10 mg PO daily; may increase to 25 mg. |
| Heart failure / CKD | 10 mg PO daily (no titration needed for these indications). |
| Renal impairment | Initiate if eGFR ≥20 mL/min/1.73 m² for HF/CKD; do not initiate for glycemic benefit at eGFR <30. Continue until dialysis. |
| Hepatic impairment | No dose adjustment. Limited data in severe disease. |
Contraindications and boxed warnings
Contraindications
- Serious hypersensitivity to empagliflozin.
- Dialysis.
2026 guideline and pivotal trial position
ACC/AHA/HFSA 2022 and subsequent 2026 focused updates identify SGLT2 inhibitors as GDMT pillars across the EF spectrum, with empagliflozin supported by both EMPEROR-Reduced and EMPEROR-Preserved. KDIGO 2024 endorses SGLT2 inhibitors as first-line in CKD with proteinuria.
EMPA-REG OUTCOME
38% RRR in CV death in T2DM with established CVD — first SGLT2i CV outcomes trial.
EMPEROR-Reduced
25% RRR in CV death or HF hospitalization in HFrEF.
EMPEROR-Preserved
21% RRR in CV death or HF hospitalization in HFpEF — first such win in HFpEF.
EMPA-KIDNEY (2023)
28% RRR in composite kidney outcome in broad CKD population.
Cross-system reasoning
Empagliflozin's indication set traverses cardiology, nephrology, and endocrinology. A 68-year-old with HFpEF, eGFR 34, and prediabetes still qualifies on HF and CKD grounds. Monitor for euglycemic DKA (held perioperatively, at minimum 3 days prior), mycotic genitourinary infection, and lower-extremity volume status. SGLT2 inhibitors may also reduce hyperuricemia and gout flares — a cross-link to rheumatology that is increasingly cited.
Key references
- FDA Label — Jardiance
- Zinman B, et al. EMPA-REG OUTCOME (NEJM 2015)PMID: 26378978
- Anker SD, et al. EMPEROR-Preserved (NEJM 2021)PMID: 34449189
- The EMPA-KIDNEY Collaborative Group (NEJM 2023)PMID: 36331190
Related clinical reading
Explore Empagliflozin in Ailva
Ailva is a free clinical intelligence platform for NPI-verified US physicians. Get evidence-based answers with verified citations from 16M+ indexed papers — plus free CME credits.
This reference is for US-licensed physicians and is not a substitute for the full FDA prescribing information. Dosing in special populations, drug interactions, and emerging safety information should be verified against the current manufacturer label and society guidelines before prescribing.